Display options
Cite
Brafford MV, Glode A. Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J Adv Pract Oncol. 2014;5(1):24-9doi: 10.6004/jadpro.2014.5.1.8.
Brafford, M. V., & Glode, A. (2014). Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. Journal of the advanced practitioner in oncology, 5(1), 24-9. https://doi.org/10.6004/jadpro.2014.5.1.8
Brafford, Megan V, and Glode, Ashley. "Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting." Journal of the advanced practitioner in oncology vol. 5,1 (2014): 24-9. doi: https://doi.org/10.6004/jadpro.2014.5.1.8
Brafford MV, Glode A. Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J Adv Pract Oncol. 2014 Jan;5(1):24-9. doi: 10.6004/jadpro.2014.5.1.8. PMID: 25032030; PMCID: PMC4093458.
Copy Download .nbib Format: NLM
Share it on

J Adv Pract Oncol. 2014 Jan;5(1):24-9. doi: 10.6004/jadpro.2014.5.1.8.

Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting.

Journal of the advanced practitioner in oncology

Megan V Brafford, Ashley Glode

Affiliations

  1. Baptist Health Lexington, Lexington, Kentucky; Medical University of South Carolina, Charleston, South Carolina.

PMID: 25032030 PMCID: PMC4093458 DOI: 10.6004/jadpro.2014.5.1.8

Abstract

Despite the appropriate use of pharmacologic and nonpharmacologic preventative measures, chemotherapy-induced nausea and vomiting (CINV) can be debilitating and can decrease quality of life for many patients. In addition, patients may be unwilling to continue chemotherapy treatment due to the uncontrollable nausea and vomiting associated with their therapy. Refractory CINV can occur at any point in a treatment cycle, despite adequate therapy for acute and delayed CINV. Current prevention strategies include using serotonin (5-HT3) receptor antagonists, corticosteroids, and/or neurokinin-1 receptor antagonists. Unfortunately, more pharmacologic options are needed to treat refractory CINV. The current standard of care for the treatment of refractory CINV includes phenothiazines, metoclopramide, butyrophenones, corticosteroids, cannabinoids, anticholinergics, and 5-HT3 receptor antagonists. Olanzapine, an atypical antipsychotic agent of the thiobenzodiazepine class, has the ability to target many different receptors, making it an attractive antiemetic agent.

References

  1. J Support Oncol. 2011 Sep-Oct;9(5):188-95 - PubMed
  2. Ann Oncol. 2010 May;21 Suppl 5:v232-43 - PubMed
  3. J Exp Clin Cancer Res. 2009 Sep 23;28:131 - PubMed
  4. Support Care Cancer. 2005 Jul;13(7):529-34 - PubMed
  5. Support Care Cancer. 2013 Jun;21(6):1655-63 - PubMed
  6. Support Care Cancer. 2007 Nov;15(11):1285 - PubMed
  7. Drugs. 2009;69(5):515-33 - PubMed
  8. J Pain Symptom Manage. 2003 Jun;25(6):578-82 - PubMed
  9. Cancer Invest. 2004;22(3):383-8 - PubMed
  10. J Pain Symptom Manage. 2002 Jun;23(6):526-32 - PubMed

Publication Types